Treatment of b-cell mediated immune disorders by t-cell mediated depletion of b cells, plasmablasts and plasma cells
A bispecific T-cell engaging protein effectively addresses the limitations of CAR-T therapy by using T-cells to selectively eliminate B-cells, providing a safer and more efficient treatment for autoimmune disorders.
WO2025207816A9 Publication Date: 2026-01-29CUE BIOPHARMA INC
0 Cites 0 Cited by
Patent Information
- Application Number
- PCT/US2025/021625
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2024-05-14
- Filing Date
- 2025-03-26
- Publication Date
- 2026-01-29
AI Technical Summary
Technical Problem
Current CAR-T therapy for autoimmune disorders is expensive, complex, and poses risks such as cytokine release syndrome and cancer, necessitating a safer and more efficient method for B-cell depletion.
Method used
Administering a bispecific T-cell engaging protein (TEP) that binds to B cells, utilizing peptide-major histocompatibility complexes and B-cell targeting components to activate T-cells for selective B-cell elimination, leveraging the patient's existing T-cell repertoire to reduce or eliminate B cells.
Benefits of technology
The T-cell mediated approach achieves a more complete B-cell depletion with reduced inflammatory responses, offering a safer and off-the-shelf solution for autoimmune and immune-mediated disorders.
✦ Generated by Eureka AI based on patent content.
Abstract
This disclosure provides compositions and methods for T-cell mediated depletion of B cells. The compositions and methods may be used, for example, for the treatment of autoimmune disorders, immune-mediated inflammation disorders and other B-cell mediated immune disorders. In embodiments, the depletion is effected by methods comprising administering to an individual a T cell engaging protein ("TEP"), wherein the TEP comprises: (i) a peptide-major histocompatibility complex ("pMHC") comprising a peptide epitope, a β2-microglobulin ("β2M") polypeptide, and an MHC class I heavy chain polypeptide; (ii) an immunoglobulin ("Ig") Fc polypeptide; (iii) at least one B-cell targeting component; and (iv) optionally one or more activating immunomodulatory polypeptides, wherein each of the at least one B-cell targeting components of the TEP binds to a B cell binding partner on a B cell, a plasmablast, and / or a plasma cell.
Need to check novelty before this filing date? Find Prior Art